vildagliptin

ビルダグリプチン


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2017/01/23 01:54:12」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.
  • Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W.SourceNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA Novartis Pharma AG, Basel, Switzerland Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum Helsinki of Helsinki, Finland.
  • Diabetes, obesity & metabolism.Diabetes Obes Metab.2011 Oct;13(10):947-54. doi: 10.1111/j.1463-1326.2011.01467.x.
  • Aim: Assess safety/tolerability and efficacy of the DPP-4 inhibitor vildagliptin in 515 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Methods: Double-blind, randomized, parallel-group, placebo-controlled, 24-week clinical trial assessing safety and effic
  • PMID 21733061
  • Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus.
  • Ghatak SB, Patel DS, Shanker N, Srivastava A, Deshpande SS, Panchal SJ.SourceDepartment of Pharmacology, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad-382 481, Gujarat, India. ghataksom16@gmail.com.
  • Current diabetes reviews.Curr Diabetes Rev.2011 Sep 15. [Epub ahead of print]
  • Type 2 diabetes mellitus causes significant morbidity and mortality on account of its progressive nature and results in considerable burden on healthcare resources. Current treatment strategies have only limited long-term efficacy and tolerability given the progressive nature of the disease leading
  • PMID 21916836

Japanese Journal

  • 最新の論文紹介 持続血糖モニター(CGM)によるDPP-4阻害薬ビルダグリプチンとシタグリプチン投与時における血糖変動の比較 : クロスオーバー試験による検討
  • 坂本 昌也
  • Life style medicine : journal of life style medicine 7(2), 125-128, 2013-02
  • NAID 40019560692
  • Pancreatitis with Pancreatic Tail Swelling Associated with Incretin-based Therapies Detected Radiologically in Two Cases of Diabetic Patients with End-Stage Renal Disease
  • Nakata Hirosuke,Sugitani Seita,Yamaji Shuhei,Otsu Satoko,Higashi Yoshihito,Ohtomo Yumiko,Inoue Gen
  • Internal Medicine 51(21), 3045-3049, 2012
  • … A 75-year-old woman with a history of liraglutide use and a 68-year-old man with a history of vildagliptin use both presented with nausea. …
  • NAID 130002061953

Related Links

(vildagliptin)に関する第III相臨床試験結果が米国糖尿病学会で発表 単剤および他の経口糖尿病治療薬との併用で、有意な血糖降下作用が示される 6月9日から13日までワシントンDCで開催された第66回米国糖尿病学会(ADA)年次 ...
Vildagliptin: clinical program Most data available on vildagliptin until now have come from company-sponsored studies designed for registration purposes. The drug has been evaluated in an extensive, ongoing clinical program, involving ...


Related Pictures

Description Vildagliptin synthesis.png : Galvus 50mg, Content: VildagliptinFile:Vildagliptin Structural Formulae.png vildagliptin tablets vildagliptin tabletswhat is vildagliptin vildagliptin is an  of vildagliptin chemical name vildagliptin



★リンクテーブル★
リンク元ビルダグリプチン

ビルダグリプチン」

  [★]

vildagliptin
エクア(ノバルティスファーマ)
経口血糖降下薬DPP-4阻害薬